A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard o...

Full description

Bibliographic Details
Main Authors: Anna V. Tinker, Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, Amit M. Oza
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Current Oncology
Subjects:
epithelial ovarian cancer
PARP inhibitors
BRCA
homologous recombination repair
Online Access:https://www.mdpi.com/1718-7729/29/6/348

Internet

https://www.mdpi.com/1718-7729/29/6/348

Similar Items